Metabolic Tests Ignored in Medicaid Patients on Antipsychotics (CME/CE): “Antipsychotic-induced metabolic disturbances receive little attention among Medicaid patients treated with second-generation antipsychotics, according to an analysis of more than 100,000 cases.”
Antipsychotic-induced metabolic disturbances receive little attention among Medicaid patients treated with second-generation drugs, according to an analysis of more than 100,000 cases.
Slightly more than a quarter of patients on antipsychotics had assessments of blood glucose levels, and about 10% had assessments of lipid levels.
FDA-mandated changes in labeling for atypical or second-generation antipsychotics had no impact on the frequency of blood glucose assessment and was associated with only a small increase in the monitoring of lipid levels.
—-